focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

27 Sep 2006 07:00

Omega Diagnostics Group PLC27 September 2006 Omega Diagnostics Group PLC 26-Sep-2006 Omega Diagnostics Group PLC (formerly Quintessentially English PLC) (the "Company") Interim Results The Company announces its interim results for the six month period to 30th June2006. These interim results do not include any results for Omega DiagnosticsLimited ("Omega"), the acquisition of which was announced on 24th August 2006and unanimously approved by shareholders at the EGM on 18th September 2006. Since the Company's Admission to AIM in March 2004 it has continued to evaluatea number of potential acquisitions and this has resulted in the purchase ofOmega. During the six months ended 30th June 2006, there was a turnover in respect ofthe Company (excluding Omega) of £Nil, and a loss after tax of £73,218, the bulkof which related to abort fees incurred on prospective acquisitions paid toadvisers undertaking due diligence. No Company directors received anyremuneration during the period and no dividend is recommended. The future Omega manufactures and distributes test kits for tropical and other diseases ona global basis, selling product through a strong distribution network in over100 countries and which it has been involved in for the past 19 years. Omega hasidentified a number of prospective and related acquisitions and intends to growin this way. Michael Gurner will be staying on as a non-executive director and Robert Coe andGraham Ashley have resigned following the EGM. David Evans has become Chairmanand Andrew Shepherd and Kieron Harbinson have joined the Board as ChiefExecutive and Finance Director respectively. For further information: Omega Diagnostics Group PLCMr Michael Gurner, 07768 231 731 Profit and Loss AccountFor the period 01/01/06 to 30/06/06 Note Period Ended 30/06 Period Ended 30/06 /2006 (unaudited) /2005 (unaudited) £ £ Turnover - -Administrative expenses (75,850) (60,633)Operating Loss (75,850) (60,633)Interest Receivable 2,674 4,382Interest Payable (42) (32)Loss on ordinary activities before taxation 1 (73,218) (56,283)Taxation - -Loss on ordinary activities after taxation (73,218) (56,283)Basic and diluted earnings per Ordinary share (pence) (0.66) (0.50)Dividends per share (pence) 0 0 Balance SheetAs at 30/06/06 Note 30/06/2006 30/06/2005 (unaudited) (unaudited) £ £ £ £ Fixed AssetsInvestments 2 2Current AssetsPrepayments 3,825 0Cash at bank in hand 124,820 198,277Current LiabilitiesCreditors: Amounts falling (80,122) (48,120)due within one yearNet current assets 48,523 150,157Total assets less current 48,525 150,159liabilitiesCalled up share capital 2 111,769 111,769Share premium 3 167,867 167,867Profit and loss account (231,111) (129,477)Equity shareholders funds 48,525 150,159Net assets per share (pence) 4 0.43p 1.34p Cash Flow Statement For the period from 01/01/06 to 30/06/06 Note Period Ended 30/06 Period Ended 30/06 /2006 (unaudited) /2005 (unaudited) £ £ Net cash inflow from operating activities (29,938) (28,677)Returns on investment and servicing of finance:Interest received 2,674 4,382Interest payable (42) (32)Decrease in cash (27,306) (24,327) Notes to the Interim Report 1. Loss on ordinary activities before taxation The loss for the period is representative of operational overheads incurred inthe period. 2. Called up share Capital The issued share capital compromises 11,176,865 ordinary shares of 1p each,consisting of 200 shares of 1p each issued as two £1 subscriber shares onincorporation and converted into 1p shares on 23rd February 2004, 6,666,665ordinary shares of 1p each issued on 24th February 2004 and 4,510,000 ordinaryshares of 1p each issued on 18th March 2004. 3. Share premium The share premium represents: £ Premium arising on issues of ordinary shares in the period ended 31/12/2004 213,731Expenses of shares issues in the period ending 31/12/2004 (45,864) At 30th June 2006 167,867 4. Net assets per share The calculation of net assets per share is based on the net assets at the end ofthe period of £48,525 and on the number of ordinary shares in issue (11,176,865)at 30th June 2006. 5. Preparation of Interim Report The interim financial information for the period from 1 January 2006 to 30thJune 2006 was approved by the directors on 26 September 2006. 6. Financial information The financial information in this statement does not constitute statutoryaccounts within the meaning of section 240 of the Companies Act 1985. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Sep 20237:00 amRNSAGM Statement
1st Sep 202310:29 amRNSUpdate on proposed Share Reorganisation
31st Aug 20237:00 amRNSProposed Share Reorganisation Timetable
22nd Aug 20237:00 amRNSDirectorate Change
17th Aug 20237:00 amRNSBoard Appointment
15th Aug 20231:45 pmRNSDirector/PDMR Shareholding
14th Aug 20237:00 amRNSPosting of Annual Report and confirmation of AGM
3rd Aug 20237:00 amRNSFinal Results
27th Jul 20237:00 amRNSNotice of Results
26th Jul 20232:10 pmRNSHolding(s) in Company
6th Jun 202311:19 amRNSHolding(s) in Company
5th Jun 20234:51 pmRNSHolding(s) in Company
2nd Jun 20232:45 pmRNSHolding(s) in Company
22nd May 20235:33 pmRNSHolding(s) in Company
10th May 20237:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
9th May 20233:42 pmRNSDirector/PDMR Shareholding
21st Apr 20239:48 amRNSHolding(s) in Company
19th Apr 20239:31 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSTrading Update
22nd Mar 20235:57 pmRNSBlock Listing Six Monthly Return
22nd Mar 20233:00 pmRNSHolding(s) in Company
6th Mar 20232:31 pmRNSHolding(s) in Company
27th Jan 20233:03 pmRNSHolding(s) in Company
27th Jan 20239:36 amRNSDirector/PDMR Shareholding
18th Jan 20237:00 amRNSTrading update
16th Jan 202310:56 amRNSHolding(s) in Company
6th Jan 20237:00 amRNSUS expansion update
3rd Jan 202312:34 pmRNSHolding(s) in Company
13th Dec 20224:40 pmRNSSecond Price Monitoring Extn
13th Dec 20224:35 pmRNSPrice Monitoring Extension
13th Dec 202212:01 pmRNSHolding(s) in Company
30th Nov 20229:35 amRNSHolding(s) in Company
25th Nov 20227:00 amRNSReceipt of deferred consideration
24th Nov 20227:00 amRNSHalf-year Report
23rd Nov 20224:41 pmRNSSecond Price Monitoring Extn
23rd Nov 20224:36 pmRNSPrice Monitoring Extension
23rd Nov 20222:05 pmRNSSecond Price Monitoring Extn
23rd Nov 20222:00 pmRNSPrice Monitoring Extension
18th Nov 202212:09 pmRNSHolding(s) in Company
16th Nov 20222:06 pmRNSSecond Price Monitoring Extn
16th Nov 20222:00 pmRNSPrice Monitoring Extension
15th Nov 20227:00 amRNSConfirmation of Results and Investor Presentation
14th Nov 20227:00 amRNSPartnership agreement with Software Provider
8th Nov 20229:04 amRNSLaunch of new all-employee share incentive plan
26th Oct 20222:50 pmRNSResult of AGM
26th Oct 20227:00 amRNSAGM Statement and Notice of Results
11th Oct 20227:00 amRNSScientific Director to present at FIDHC
5th Oct 20227:00 amRNSPositive WHO data received for VISITECT® CD4 test
27th Sep 20227:00 amRNSPosting of Annual Report and confirmation of AGM
20th Sep 202212:05 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.